Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Pirker

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
MDR1 gene expression and prognostic factors in primary breast carcinomasJ Wallner, D Depisch, M Hopfner, et al.
Cancer Research|September 1, 1989
Enhancement of the activity of immunotoxins by analogues of verapamilR Pirker, D J FitzGerald, M Raschack, et al.
Breast Cancer Research and Treatment|January 1, 1993
Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin CW Scheithauer, G Kornek, K Haider, et al.
British Journal of Cancer|October 1, 1993
MDR1 gene expression in primary colorectal carcinomasR Pirker, J Wallner, A Gsur, et al.
Nephron|January 1, 1995
MDR1 gene expression in lymphocytes of patients with renal transplantsM Götzl, J Wallner, A Gsur, et al.
Clinical and Experimental Rheumatology|April 4, 2003
Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritisT Stranzl, J Wolf, B F Leeb, et al.
Leukemia & Lymphoma|April 1, 1994
MDR1 gene expression in chronic lymphocytic leukemiaJ Wallner, H Gisslinger, B Gisslinger, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapyT Berger, R Malayeri, A Doppelbauer, et al.
Annals of the Rheumatic Diseases|September 4, 2004
Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritisJ Wolf, T Stranzl, M Filipits, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trialC Manegold, U Gatzemeier, J von Pawel, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
MDR1 gene expression and prognostic factors in primary breast carcinomasJ Wallner, D Depisch, M Hopfner, et al.
Cancer Research|September 1, 1989
Enhancement of the activity of immunotoxins by analogues of verapamilR Pirker, D J FitzGerald, M Raschack, et al.
Breast Cancer Research and Treatment|January 1, 1993
Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin CW Scheithauer, G Kornek, K Haider, et al.
British Journal of Cancer|October 1, 1993
MDR1 gene expression in primary colorectal carcinomasR Pirker, J Wallner, A Gsur, et al.
Nephron|January 1, 1995
MDR1 gene expression in lymphocytes of patients with renal transplantsM Götzl, J Wallner, A Gsur, et al.
Clinical and Experimental Rheumatology|April 4, 2003
Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritisT Stranzl, J Wolf, B F Leeb, et al.
Leukemia & Lymphoma|April 1, 1994
MDR1 gene expression in chronic lymphocytic leukemiaJ Wallner, H Gisslinger, B Gisslinger, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapyT Berger, R Malayeri, A Doppelbauer, et al.
Annals of the Rheumatic Diseases|September 4, 2004
Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritisJ Wolf, T Stranzl, M Filipits, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trialC Manegold, U Gatzemeier, J von Pawel, et al.
Pageof 8